Angiotensin‐converting enzyme inhibitor works as a scar formation inhibitor by down‐regulating Smad and TGF‐β‐activated kinase 1 (TAK1) pathways in mice

• Published in: British journal of pharmacology Vol. 175; no. 22; pp. 4239 - 4252
• Main Authors: Tan, Wei‐Qiang, Fang, Qing‐Qing, Shen, Xiao Z, Giani, Jorge F, Zhao, Tuantuan V, Shi, Peng, Zhang, Li‐Yun, Khan, Zakir, Li, You, Li, Liang, Xu, Ji‐Hua, Bernstein, Ellen A, Bernstein, Kenneth E
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.11.2018
• Subjects: Angiotensin-Converting Enzyme Inhibitors - pharmacology; Animals; Disease Models, Animal; Male; MAP Kinase Kinase Kinases - antagonists & inhibitors; MAP Kinase Kinase Kinases - deficiency; MAP Kinase Kinase Kinases - metabolism; Mice; Mice, Knockout; Research Paper; Research Papers; Signal Transduction - drug effects; Smad Proteins - antagonists & inhibitors; Smad Proteins - metabolism

Background and Purpose Angiotensin‐converting enzyme (ACE), an important part of the renin‐angiotensin system, is implicated in stimulating the fibrotic processes in the heart, lung, liver and kidney, while an ACE inhibitor (ACEI) promotes physiological tissue repair in these organs. The mechanism i...